Therapeutic compounds: patent evaluation of WO2011011652A1.

Abstract

A series of sulfonamide derivatives, incorporating azabicyclo[3.2.1]octane and phenyl-propyl scaffolds, were prepared by a succession of original steps. The compounds are claimed to act as antagonists of the C-C chemokine receptor 5 (CCR5) involved in the entry of HIV-1 to cells, but only semi-quantitative antiviral data are provided. HIV entry inhibitors, including CCR5 antagonists, are clinically used for the treatment of this viral infection; the compounds claimed in the patent, possessing a new and original scaffold, seem to be of interest for developing novel antiviral agents belonging to this class.

• Authors: Claudiu T Supuran
• Journal: Expert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 21 Issue 9 Pg. 1491-5 (Sep 2011) ISSN: 1744-7674 [Electronic] England
• PMID: 21548842 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• CCR5 Receptor Antagonists
• HIV Fusion Inhibitors
• Indicators and Reagents
• Sulfonamides

Topics

• Antiviral Agents (chemical synthesis, pharmacology)
• CCR5 Receptor Antagonists
• HIV Fusion Inhibitors (chemical synthesis, pharmacology)
• Indicators and Reagents
• Patents as Topic
• Sulfonamides (chemical synthesis)